Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10) 10
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
female (9) 9
index medicus (9) 9
male (9) 9
cancer (8) 8
aged (7) 7
life sciences (7) 7
middle aged (7) 7
chemoradiotherapy (6) 6
clinical trials (6) 6
fluorouracil - administration & dosage (6) 6
oncology (6) 6
adult (5) 5
chemotherapy (5) 5
deoxycytidine - analogs & derivatives (5) 5
oxaliplatin (5) 5
[ sdv.spee ] life sciences [q-bio]/santé publique et épidémiologie (4) 4
capecitabine (4) 4
care and treatment (4) 4
deoxycytidine - administration & dosage (4) 4
disease-free survival (4) 4
hematology, oncology and palliative medicine (4) 4
organoplatinum compounds - administration & dosage (4) 4
radiotherapy (4) 4
santé publique et épidémiologie (4) 4
treatment outcome (4) 4
5-fluorouracil (3) 3
adenocarcinoma (3) 3
aged, 80 and over (3) 3
antineoplastic combined chemotherapy protocols (3) 3
carcinoma (3) 3
colorectal cancer (3) 3
fluorouracil - analogs & derivatives (3) 3
gemcitabine (3) 3
mesh : adult (3) 3
mesh : aged (3) 3
mesh : antineoplastic combined chemotherapy protocols (3) 3
mesh : female (3) 3
mesh : humans (3) 3
mesh : male (3) 3
mesh : middle aged (3) 3
pancreatic cancer (3) 3
pancreatic neoplasms - drug therapy (3) 3
radiology, nuclear medicine & medical imaging (3) 3
rectal cancer (3) 3
analysis (2) 2
cancer therapies (2) 2
cetuximab (2) 2
cisplatin - administration & dosage (2) 2
comparative analysis (2) 2
docetaxel (2) 2
fluorouracil (2) 2
fluorouracil - therapeutic use (2) 2
folfirinox (2) 2
leucovorin - administration & dosage (2) 2
leucovorin - therapeutic use (2) 2
medical prognosis (2) 2
mesh : chemoradiotherapy (2) 2
mesh : fluorouracil (2) 2
mesh : pancreatic neoplasms (2) 2
mesh : treatment outcome (2) 2
neoadjuvant therapy - adverse effects (2) 2
neoplasm staging (2) 2
open-label (2) 2
pancreatic neoplasms (2) 2
patients (2) 2
postoperative chemoradiotherapy (2) 2
product development (2) 2
radiation therapy (2) 2
rectal neoplasms - pathology (2) 2
rectal neoplasms - therapy (2) 2
retrospective studies (2) 2
surgery (2) 2
survival (2) 2
therapy (2) 2
total mesorectal excision (2) 2
tumors (2) 2
usage (2) 2
[sdv.spee]life sciences [q-bio]/santé publique et épidémiologie (1) 1
abridged index medicus (1) 1
adjuvant treatment (1) 1
adolescent (1) 1
age factors (1) 1
antibodies, monoclonal, humanized - therapeutic use (1) 1
antineoplastic agents (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic combinated chemotherapy protocols/therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
anus neoplasms - radiotherapy (1) 1
anus neoplasms - therapy (1) 1
bevacizumab (1) 1
biomarkers (1) 1
ca-19-9 (1) 1
ca-19-9 antigen - blood (1) 1
ca-19-9 antigen/blood (1) 1
ca19-9 (1) 1
cabazitaxel (1) 1
camptothecin - administration & dosage (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
by Conroy, Thierry and Hammel, Pascal and Hebbar, Mohamed and Ben Abdelghani, Meher and Wei, Alice C and Raoul, Jean-Luc and Choné, Laurence and Francois, Eric and Artru, Pascal and Biagi, James J and Lecomte, Thierry and Assenat, Eric and Faroux, Roger and Ychou, Marc and Volet, Julien and Sauvanet, Alain and Breysacher, Gilles and Di Fiore, Frédéric and Cripps, Christine and Kavan, Petr and Texereau, Patrick and Bouhier-Leporrier, Karine and Khemissa-Akouz, Faiza and Legoux, Jean-Louis and Juzyna, Béata and Gourgou, Sophie and O’Callaghan, Christopher J and Jouffroy-Zeller, Claire and Rat, Patrick and Malka, David and Castan, Florence and Bachet, Jean-Baptiste and Canadian Canc Trials Grp and Unicanc-GI-PRODIGE Grp and Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group
The New England Journal of Medicine, ISSN 0028-4793, 12/2018, Volume 379, Issue 25, pp. 2395 - 2406
In a prospective, randomized trial involving patients with resected pancreatic cancer, adjuvant combination chemotherapy with FOLFIRINOX resulted in a median... 
TRIAL | MEDICINE, GENERAL & INTERNAL | MULTICENTER | RESECTION | OPEN-LABEL | PHASE-3 | CHEMOTHERAPY | Prospective Studies | Organometallic Compounds - adverse effects | Humans | Middle Aged | Proportional Hazards Models | Male | Lung Diseases, Interstitial - chemically induced | Pancreatic Neoplasms - drug therapy | Disease-Free Survival | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Organometallic Compounds - therapeutic use | Adult | Deoxycytidine - adverse effects | Female | Leucovorin - therapeutic use | Aged | Chemotherapy, Adjuvant | Deoxycytidine - analogs & derivatives | Drug Combinations | Chemotherapy | Usage | Care and treatment | Gemcitabine | Pancreatic cancer | Comparative analysis | Cancer | Adenocarcinoma | Fees & charges | Nuclear magnetic resonance--NMR | Cardiovascular disease | Metastasis | Grants | Cancer therapies | Survival | Metastases | Irinotecan | Pneumonitis | Oxaliplatin | Medical prognosis | Safety | Life Sciences | Human health and pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer
by Jean-Pierre Gérard and David Azria and Sophie Gourgou-Bourgade and Isabelle Martel-Lafay and Christophe Hennequin and Pierre-Luc Etienne and Véronique Vendrely and Eric François and Guy de La Roche and Olivier Bouché and Xavier Mirabel and Bernard Denis and Laurent Mineur and Jean-François Berdah and Marc-André Mahé and Yves Bécouarn and Olivier Dupuis and Gérard Lledo and Jean-François Seitz and Laurent Bedenne and Béata Juzyna and Thierry Conroy
Journal of Clinical Oncology, ISSN 0732-183X, 12/2012, Volume 30, Issue 36, pp. 4558 - 4565
Purpose The ACCORD 12 trial investigated the value of two different preoperative chemoradiotherapy (CT-RT) regimens in T3-4 Nx M0 resectable rectal cancer.... 
PHASE-III TRIAL | ONCOLOGY | PREOPERATIVE RADIOTHERAPY | POSTOPERATIVE CHEMORADIOTHERAPY | MRC CR07 | OXALIPLATIN | RECURRENCE | CARCINOMA | Radiotherapy Dosage | Leucovorin - administration & dosage | Fluorouracil - analogs & derivatives | Capecitabine | Deoxycytidine - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Chemoradiotherapy, Adjuvant - adverse effects | Male | Treatment Outcome | Rectal Neoplasms - therapy | Disease-Free Survival | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - adverse effects | Female | Aged | Rectal Neoplasms - pathology | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: Phase II UNICANCER trial ORL03
by Fayette, Jérôme and Guigay, Joel and Le Tourneau, Christophe and Degardin, Marian and Peyrade, Frederic and Neidhardt, Eve-Marie and Sablin, Marie-Paule and Even, Caroline and Orlandini, Florence and Juzyna, Béata and Bellera, Carine
Oncotarget, ISSN 1949-2553, 02/2017, Volume 8, Issue 31, pp. 51830 - 51839
Treatments are limited after platinum Cetuximab or anti-PD1 failure for patients with recurrent/metastatic head and neck squamous cell carcinoma. Cabazitaxel... 
Head and neck cancer | Platinum failure | Recurrent | Cabazitaxel | head and neck cancer | METHOTREXATE | OPEN-LABEL | METASTATIC HEAD | DOCETAXEL | CANCER | CELL BIOLOGY | CAPECITABINE | CETUXIMAB | platinum failure | COMPARING CISPLATIN | CISPLATIN PLUS FLUOROURACIL | recurrent
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial
by Gérard, Jean-Pierre and Chamorey, Emmanuel and Gourgou-Bourgade, Sophie and Benezery, Karène and de Laroche, Guy and Mahé, Marc-André and Boige, Valérie and Juzyna, Béata
Radiotherapy and Oncology, ISSN 0167-8140, 2015, Volume 115, Issue 2, pp. 246 - 252
Abstract Background During the ACCORD 12 randomized trial, an evaluation of the clinical tumor response was prospectively performed after neoadjuvant... 
Hematology, Oncology and Palliative Medicine | Organ preservation | Rectal cancer | Clinical complete response | Neoadjuvant treatment | Conservative treatment | SURGERY | PREOPERATIVE CHEMORADIATION | SEE POLICY | POSTOPERATIVE CHEMORADIOTHERAPY | TUMOR RESPONSE | SPHINCTER PRESERVATION | TOTAL MESORECTAL EXCISION | CHEMOTHERAPY | THERAPY | ONCOLOGY | RADIOTHERAPY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Fluorouracil - analogs & derivatives | Capecitabine | Rectum - pathology | Deoxycytidine - administration & dosage | Humans | Middle Aged | Male | Treatment Outcome | Rectal Neoplasms - therapy | Chemoradiotherapy | Disease Progression | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - adverse effects | Female | Deoxycytidine - analogs & derivatives | Clinical trials | Adjuvant treatment | Colorectal cancer | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial
by Conroy, Thierry, Prof and Galais, Marie-Pierre, MD and Raoul, Jean-Luc, Prof and Bouché, Olivier, Prof and Gourgou-Bourgade, Sophie, MSc and Douillard, Jean-Yves, Prof and Etienne, Pierre-Luc, MD and Boige, Valérie, MD and Martel-Lafay, Isabelle, MD and Michel, Pierre, Prof and Llacer-Moscardo, Carmen, MD and François, Eric, MD and Créhange, Gilles, MD and Abdelghani, Meher Ben, MD and Juzyna, Beata, MSc and Bedenne, Laurent, Prof and Adenis, Antoine, Prof and UNICANCER-GI Grp and Federation Francophone Cancerol Di and Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 3, pp. 305 - 314
Summary Background Definitive chemoradiotherapy is a curative treatment option for oesophageal carcinoma, especially in patients unsuitable for surgery. The... 
Hematology, Oncology and Palliative Medicine | 5-FLUOROURACIL | ONCOLOGY | LOCALIZED CARCINOMA | CLINICAL-TRIALS | FOLLOW-UP | OXALIPLATIN | QUALITY-OF-LIFE | FOLINIC ACID | II TRIAL | CHEMOTHERAPY | RADIATION-THERAPY | Humans | Middle Aged | Male | Chemoradiotherapy | Cisplatin - administration & dosage | Disease-Free Survival | Fluorouracil - therapeutic use | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Esophageal Neoplasms - mortality | Adult | Female | Leucovorin - therapeutic use | Aged | Esophageal Neoplasms - therapy | Organoplatinum Compounds - therapeutic use | Clinical trials | Care and treatment | Leucovorin | Product development | Esophageal cancer | Life Sciences | Santé publique et épidémiologie
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Impact of single‐nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD‐12/PRODIGE‐2 phase III trial
by Boige, Valérie and Mollevi, Caroline and Gourgou, Sophie and Azria, David and Seitz, Jean‐François and Vincent, Marc and Bigot, Ludovic and Juzyna, Beata and Miran, Isabelle and Gerard, Jean‐Pierre and Laurent‐Puig, Pierre
International Journal of Cancer, ISSN 0020-7136, 12/2019, Volume 145, Issue 11, pp. 3163 - 3172
We examined whether 66 germline single‐nucleotide polymorphisms (SNPs) in 10 candidate genes would predict clinical outcome in 316 patients with resectable... 
single‐nucleotide polymorphism | ERCC1 | rectal cancer | ERCC2 | XPA | chemoradiotherapy | oxaliplatin | Dworak score | pathological response | pharmacogenetics | Care and treatment | Pharmacogenetics | Analysis | Genes | DNA | Colorectal cancer | Clinical trials | Genetic research | Genetic aspects | Single nucleotide polymorphisms | DNA repair | Cancer | Toxicity | Medical services | Methylenetetrahydrofolate reductase | Single-nucleotide polymorphism | Genetic diversity | Regression analysis | Radiation therapy | Nucleotides | Multivariate analysis | Patients | Regression models | Oxaliplatin | Rectum | ERCC1 protein | Toxic diseases | Repair | Deoxyribonucleic acid--DNA | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Applying the Longitudinal Model from Item Response Theory to Assess Health-Related Quality of Life in the PRODIGE 4/ACCORD 11 Randomized Trial
by Barbieri, Antoine and Anota, Amélie and Conroy, Thierry and Gourgou-Bourgade, Sophie and Juzyna, Beata and Bonnetain, Franck and Lavergne, Christian and Bascoul-Mollevi, Caroline
Medical Decision Making, ISSN 0272-989X, 7/2016, Volume 36, Issue 5, pp. 615 - 628
Introduction. A new longitudinal statistical approach was compared to the classical methods currently used to analyze health-related quality-of-life (HRQoL)... 
longitudinal analysis | health-related quality of life | item response theory | generalized linear mixed model | EORTC QLQ-C30 | SHIFT | IMPACT | FOLFIRINOX | MEDICAL INFORMATICS | BEVACIZUMAB | HEALTH CARE SCIENCES & SERVICES | GEMCITABINE | Humans | Middle Aged | Pancreatic Neoplasms - pathology | Male | Pancreatic Neoplasms - drug therapy | Neoplasm Metastasis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Adult | Female | Aged | Pancreatic Neoplasms - physiopathology | Longitudinal Studies | Care and treatment | Usage | Analysis | Pancreatic cancer | Item response theory | Risk factors | Quality of life | Antineoplastic Combined Chemotherapy Protocols | Life Sciences | Santé publique et épidémiologie | Pancreatic Neoplasms
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Evolution of pain in patients with metastatic pancreatic carcinoma treated with FOLFIRINOX or gemcitabine in a randomized phase III study (ACCORD11/PRODIGE4)
by Gourgou, Sophie and Jarlier, Marta and Barbieri, Antoine and Desseigne, Françoise and Ychou, Marc and Bouche, Olivier and Juzyna, Beata and Conroy, Thierry
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. e15251 - e15251
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Impact of Immune response-associated gene polymorphisms on tumor response in rectal cancer patients treated with capecitabine +/- oxaliplatine and radiation in the ACCORD-12/PRODIGE-2 phase III trial
by Boige, Valerie and Mollevi, Caroline and Chaput, Nathalie and Gourgou, Sophie and Azria, David and Seitz, Jean-François and Bigot, Ludovic and Juzyna, Beata and Miran, Isabelle and Gerard, Jean-Pierre and Laurent-Puig, Pierre
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. e15151 - e15151
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4)
by Robert, Marie and Jarlier, Marta and Gourgou, Sophie and Desseigne, Françoise and Ychou, Marc and Bouché, Olivier and Juzyna, Beata and Conroy, Thierry and Bennouna, Jaafar
Oncology, ISSN 0030-2414, 12/2017, Volume 93, Issue 6, pp. 367 - 376
Objectives: Carbohydrate antigen 19-9 (CA19-9) is a sensitive and specific serum marker in pancreatic cancer. Our retrospective analysis aims to evaluate... 
Clinical Study | Biomarkers | FOLFIRINOX | CA19-9 | Metastatic pancreatic cancer | SURVIVAL | ADENOCARCINOMA | CANCER | CHEMOTHERAPY | ONCOLOGY | PACLITAXEL PLUS GEMCITABINE | CARBOHYDRATE ANTIGEN 19-9 | CA-19-9 | TUMOR-MARKER | Leucovorin - administration & dosage | Pancreatic Neoplasms - blood | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Deoxycytidine - administration & dosage | Humans | Male | Pancreatic Neoplasms - drug therapy | Disease-Free Survival | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Camptothecin - administration & dosage | Female | Aged | Retrospective Studies | CA-19-9 Antigen - blood | Deoxycytidine - analogs & derivatives | Camptothecin - analogs & derivatives | Life Sciences | Antineoplastic Combinated Chemotherapy Protocols/therapeutic use | Pancreatic Neoplasms/drug therapy | CA-19-9 Antigen/blood | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Association of polymorphisms with tumor response in rectal cancer patients treated with capecitabine +/- oxaliplatine and radiation: Pharmacogenetic analysis of ACCORD-12/PRODIGE-2 trial
by Boige, Valerie and Mollevi, Caroline and Azria, David and Gourgou, Sophie and Seitz, Jean Francois and Vincent, Marc and Bigot, Ludovic and Juzyna, Beata and Miran, Isabelle and Gerard, Jean-Pierre and Laurent-Puig, Pierre
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. 3583 - 3583
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Retrospective analysis of CA19-9 decrease in patients with metastatic pancreatic carcinoma (MPC) treated with FOLFIRINOX or gemcitabine (gem) in a randomized phase III study (ACCORD11/PRODIGE4)
by Robert, Marie and Jarlier, Marta and Conroy, Thierry and Gourgou, Sophie and Desseigne, Françoise and Ychou, Marc and Bouche, Olivier and Juzyna, Beata and Bennouna, Jaafar and Unicancer GI; PRODIGE Intergroup
Journal of Clinical Oncology, ISSN 0732-183X, 05/2014, Volume 32, Issue 15_suppl, pp. 4115 - 4115
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: Long-term results of the UNICANCER ACCORD 16 phase II trial
by Levy, Antonin and Azria, David and Pignon, Jean-Pierre and Delarochefordiere, Anne and Martel-Lafay, Isabelle and Rio, Emmanuel and Malka, David and Conroy, Thierry and Miglianico, Laurent and Becouarn, Yves and Malekzadeh, Katty and Leclercq, Julie and Juzyna, Beata and Ezra, Patrick and Lemanski, Claire and Deutsch, Eric
Radiotherapy and Oncology, ISSN 0167-8140, 2015, Volume 114, Issue 3, pp. 415 - 416
Hematology, Oncology and Palliative Medicine | 5-FLUOROURACIL | ONCOLOGY | IMMUNOTHERAPY | CHEMORADIATION | RANDOMIZED-TRIAL | MITOMYCIN | RADIOTHERAPY | INTERGROUP | COMBINATION | CARCINOMA | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Antibodies, Monoclonal, Humanized - therapeutic use | Cetuximab | Chemoradiotherapy | Anus Neoplasms - radiotherapy | Humans | Clinical Trials, Phase II as Topic | Clinical trials | Life Sciences | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial
by Edeline, Julien and Bonnetain, Franck and Phelip, Jean Marc and Watelet, Jérôme and Hammel, Pascal and Joly, Jean-Paul and Ben Abdelghani, Meher and Rosmorduc, Olivier and Bouhier-Leporrier, Karine and Jouve, Jean-Louis and Faroux, Roger and Guerin Meyer, Véronique and Assenat, Eric and Seitz, Jean Francois and Malka, David and Louvet, Christophe and Bertaut, Aurelie and Juzyna, Beata and Stanbury, Trevor and Boucher, Eveline
Journal of Clinical Oncology, ISSN 0732-183X, 02/2017, Volume 35, Issue 4_suppl, pp. 225 - 225
225 Background: No standard post-surgery adjuvant treatment is currently recommended in localized biliary tract cancer (BTC). Gemcitabine combined with... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: Tolerance and efficacy
by François, Eric and Azria, David and Gourgou-Bourgade, Sophie and Jarlier, Marta and Martel-Laffay, Isabelle and Hennequin, Christophe and Etienne, Pierre-Luc and Vendrely, Véronique and Seitz, Jean-François and Conroy, Thierry and Juzyna, Beata and Gerard, Jean-Pierre
Radiotherapy and Oncology, ISSN 0167-8140, 2013, Volume 110, Issue 1, pp. 144 - 149
Abstract Background Rectal cancer predominantly affects the elderly. Unfortunately, this age category is under-represented in clinical trials because... 
Hematology, Oncology and Palliative Medicine | Exploratory analysis | Oxaliplatin | Rectal cancer | Capecitabine | Elderly | Neoadjuvant chemoradiotherapy | ONCOLOGY | RISK | RADIOTHERAPY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | TOTAL MESORECTAL EXCISION | Age Factors | Fluorouracil - analogs & derivatives | Rectal Neoplasms - surgery | Deoxycytidine - administration & dosage | Humans | Middle Aged | Male | Treatment Outcome | Chemoradiotherapy | Rectal Neoplasms - radiotherapy | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Adult | Female | Neoadjuvant Therapy | Aged | Rectal Neoplasms - pathology | Retrospective Studies | Neoplasm Staging | Rectal Neoplasms - drug therapy | Deoxycytidine - analogs & derivatives | Clinical trials | Colorectal cancer | Organoplatinum Compounds | Antineoplastic Combined Chemotherapy Protocols | Life Sciences | Rectal Neoplasms | Deoxycytidine | Santé publique et épidémiologie | Fluorouracil
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Influence of age on chemoradiotherapy outcome in patients with rectal cancer: Exploratory analysis from the phase III study ACCORD 12/0405 PRODIGE 2
by Francois, Eric and Azria, David and Gourgou-Bourgade, Sophie and Martel-Lafay, Isabelle and Hennequin, Christophe and Etienne, Pierre-Luc and Vendrely, Veronique and Seitz, Jean Francois and Conroy, Thierry and Juzyna, Beata and Gerard, Jean-Pierce
Journal of Clinical Oncology, ISSN 0732-183X, 02/2012, Volume 30, Issue 4_suppl, pp. 550 - 550
550 Background: Preoperative radiochemotherapy (RCT) is the standard of care for patients (pts) with locally advanced rectal adenocarcinoma. However elderly... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Reply to R. Glynne-Jones et al
by Peiffert, Didier and Tournier-Rangeard, Laetitia and Gérard, Jean-Pierre and Lemanski, Claire and François, Eric and Giovannini, Marc and Mirabel, Xavier and Bouché, Olivier and Conroy, Thierry and Juzyna, Beata and Mornex, Françoise and Hannoun-Lévy, Jean-Michel and Seitz, Jean-François and Adenis, Antoine and Hennequin, Christophe and Ducreux, Michel
Journal of Clinical Oncology, ISSN 0732-183X, 01/2013, Volume 31, Issue 1, pp. 165 - 166
Anus Neoplasms - therapy | Female | Male | Chemoradiotherapy - methods | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Humans
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: A non-comparative randomized phase II trial
by Ducreux, Michel and Giovannini, Marc and Baey, Charlotte and Llacer, Carmen and Bennouna, Jaafar and Adenis, Antoine and Peiffert, Didier and Mornex, Françoise and Abbas, Moncef and Boige, Valèrie and Pignon, Jean-Pierre and Conroy, Thierry and Cellier, Patrice and Juzyna, Beata and Viret, Frédéric
Digestive and Liver Disease, ISSN 1590-8658, 2014, Volume 46, Issue 10, pp. 950 - 955
Abstract Background We performed a randomized, non-comparative phase II study evaluating docetaxel in combination with either daily continuous (protracted IV)... 
Gastroenterology and Hepatology | Pancreatic carcinoma | Radio-chemotherapy | Cisplatin | Docetaxel | ADENOCARCINOMA | CHEMORADIOTHERAPY | CANCER | GEMCITABINE | CHEMOTHERAPY | PACLITAXEL | 5-FLUOROURACIL | THERAPY | RADIOTHERAPY | GASTROENTEROLOGY & HEPATOLOGY | CONCURRENT | Drug Administration Schedule | Humans | Middle Aged | Male | Treatment Outcome | Antineoplastic Agents - administration & dosage | Chemoradiotherapy | Cisplatin - administration & dosage | Young Adult | Taxoids - administration & dosage | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Adult | Female | Aged | Pancreatic Neoplasms - mortality | Pancreatic Neoplasms - therapy | Carcinoma | Pancreatic cancer | Radiation | Clinical trials | Product development | Comparative analysis | Fluorouracil | Cancer | Index Medicus | Antineoplastic Agents | Antineoplastic Combined Chemotherapy Protocols | Life Sciences | Taxoids | Santé publique et épidémiologie | Pancreatic Neoplasms
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.